Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial

BACKGROUND: Following the approval of lisdexamfetamine dimesylate (LDX) in several European countries for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with an inadequate response to methylphenidate (MPH) treatment, the aim of the present analysis was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Coghill, David R, Banaschewski, Tobias, Lecendreux, Michel, Soutullo, César, Zuddas, Alessandro, Adeyi, Ben, Sorooshian, Shaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219557/
https://www.ncbi.nlm.nih.gov/pubmed/25378930
http://dx.doi.org/10.2147/NDT.S68273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219557/
https://www.ncbi.nlm.nih.gov/pubmed/25378930
http://dx.doi.org/10.2147/NDT.S68273

Ejemplares similares